EFTA01479577.pdf

Subject: Re: Biotech Update... Gilead beat, shares halted [C] From: Tazia Smith < E> Date: Tue, 22 Apr 2014 16:16:17 -0400 To: [email protected] Cc: Nav Gupta Paul Morris Vahe Stepanian Vinit Sahni Classification: Confidential Jeffrey - sure you see this, just making sure, Gilead shares are halted in the after-market following a significant top and bottom-line earnings beat ($1.48 vs $0.92 cons eps, $5bn on the topline vs. expecations of $3.96bn) as you know, you're long 8100 shares at an average price of $79.41, stock closed today at $72.86, just reported. Shares expected to re-open at 4:30pm From: Tazia Smith To: jeevacati n m : Paul Morris, Vahe Stepania , Nav Gupta Vinit Sahni Date: 04/02/2014 03:42 PM Subject: Biotech Update... [C] Classification: Confidential Jeffrey - Biotech forming a base to some extent (strong market backdrop, clearly) you're up $906k on your basket excluding the Ariad (outlier due to M&A prospects vs. group drivers) 1-mo price history charts below. EFTA01479577 SGMO lmo Price History BIIB lmo Price History GILD lmo Price History FMI lmo Price History Tazia Smith Director I Key Client Partners - US DB Securities Inc Deutsche Asset & Wealth Management 345 Park Avenue, 10154-0004 New York, NY, USA Tel. Fax Mobile Email EFTA01479578